Aurobindo To Lupin — Pharma Companies Under Pressure As US Price Erosion Continues
Indian pharmaceutical companies experienced robust growth in the fourth quarter of fiscal 2024, with increased sales. There was also a noticeable easing of pricing pressure on US generics, raising hopes for improvement in the market plagued by shortages.
Despite most drugmakers witnessing revenue growth in the US market during the fourth quarter, questions on price erosion stabilisation remained. Major pharma companies were expecting benign pricing erosion and the pricing environment to stabilise. However, now the data shows otherwise.
The National Average Drug Acquisition Cost's latest pricing trends show a sharp double-digit decline in April–June 2024. NADAC is the approximate invoice price that pharmacies charge for medications in the United States.
US Medicaid publishes NADAC on a weekly basis, based on a survey of actual invoices between pharmacies and wholesalers.
In Citi's analysis of top baseline molecules of Indian generic companies—20 products each for Aurobindo Pharma Ltd., Dr Reddy's Laboratories Ltd., Cipla Ltd. and Lupin Ltd.—close to 40-45% of the drug stock keeping units witnessed price increase in fiscal 2024, while the number of drug stock keeping units seeing a double-digit erosion was very less at 23%, resulting in a stable or modest generic pricing environment.
NADAC saw a sharp decline in the generic prices in April, only to fall further in May and June.
According to Citi's analysis of the top-70 products, approximately 80% have seen a double-digit price erosion in June 2024, against the average pricings in March 2024.
The average of drug prices in June indicated approximately more than 20% decline quarter-on-quarter for Dr Reddy's and Lupin and 14% decline sequentially for Aurobindo and Cipla, based on the trends in top-20 molecules.
Citi introduced downside 90-day Catalyst Watches on Aurobindo Pharma and Dr Reddy's.
Based on NADAC trends, it's quite clear that generic pricing in the US is on a downward trend after a benign environment in fiscal 2024. If these trends hold, margins and earnings may see consensus downgrades, and that may also impact valuations that currently appear elevated, according to Citi.
Here is what brokerages have to say.
Dr Reddy's Laboratories
Citi
Maintained a 'sell' rating with a target price of Rs 5,200 per share, implying a downside of 14.5%.
Witnessed competition in its top products in the US.
Impact of the pricing may be higher than the other companies.
Impact of pricing higher due to commoditised portfolios.
Jefferies
Reiterated 'underperform' rating with target price of Rs 5,010 apiece, which is a downside of 18%.
IQVIA suggests company is losing market share in its top US products.
Expects impact of loss in market share to reflect in first half of fiscal 2025.
Top products contribute $417 million.
Research and development cost could remain elevated.
New launches to offset price erosion but do not drive meaningful growth.
Strategic acquisition may fill gRevlimid void.
Aurobindo Pharma
Citi
Maintained non-consensus 'sell' with a target price of Rs 1,040 per share, implying a downside of 17.3%.
Aurobindo has highest exposure of US generics among the Indian pharma companies.
If generic pricing trends start reflecting, there is possibility of margins softening in first and second quarter of fiscal 2025.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
